Australia Health

Mayne Pharma (ASX:MYX) agreed to pay US$0.7 million to settle a civil complaint filed by attorneys general from 49 US states and territories.

AFT Pharmaceuticals (ASX:AFP) entered an exclusive license and supply agreement with Mikasa Seiyaku to commercialise its pain treatment Maxigesic IV in Japan.

Memphasys (ASX:MEM) has identified an expedited 510(k) pathway to seek clearance for its Felix Sperm Separation System.

Nexsen (ASX:NXN) has entered into a non-binding term sheet with FlashDx Shenzhen to set up a 50:50 joint venture.

Healius (ASX:HLS) entered into a binding agreement to sell its subsidiary Agilex Biolabs for an enterprise value of $160 million.

Paradigm Biopharmaceuticals (ASX:PAR) has agreed to return US$2 million to Obsidian Global GP and cancel 2,000,000 convertible notes.

Nexsen (ASX:NXN) paused its StrepSure clinical trial for product enhancements, which the company expects will delay regulatory submission by one quarter.

Ovarian cancer diagnostics company Cleo Diagnostics (ASX:COV) has commenced prototype development of a multi-biomarker blood test.

Paradigm Biopharmaceuticals (ASX:PAR) has missed a key efficacy threshold in its Phase 3 trial for knee osteoarthritis.

BCAL Diagnostics (ASX:BDX) has commenced the Australian rollout of the Avantect Multi-Cancer blood-based diagnostic test in Sydney and Melbourne.

Prescient Therapeutics (ASX:PTX) completed a $6 million capital raise to advance the clinical development of its target cancer therapy.

Patrys (ASX:PAB) has commenced human clinical testing by dosing the first participants in a Phase 1a trial for RLS-2202.